Amura is a structure-based drug discovery and pre-clinical development company dedicated to the invention of new technologies, innovative medicines and novel products for improving health.
Amura's therapeutic focus is in the areas of osteoporosis, bone metastasis, autoimmunity (e.g. rheumatoid arthritis, osteoarthritis, psoriasis, etc.), chronic pain and malaria.
Amura's AMcore scaffold is the premier chemical solution to cysteine peptidase inhibitor design.
Amura products encompass its pre-clinical therapeutic programmes and intellectual property; which will be developed by strategic alliances with globally-recognised licensing partners.
